Although resistance to TGF‐β in MPN cells has long been described23, 24 no clear mechanism has been proposed with the exception of reduced expression of SMAD4 in ET patient cells25 or reduction of TGFbRII mRNA in CD34‐positive cells from MF patients.24 Here, SMAD4 is linked to myeloproliferative neoplasm.